India, April 28 -- PTC Therapeutics, Inc. (PTCT) said it will present new long-term results from its PIVOT-HD study, offering an updated look at how its experimental Huntington's disease treatment Votoplam. The company will discuss the 24-month interim results during a webcast later today.Company to Review 24-Month Findings
PTC will host a call at 4:30 p.m. ET to outline how patients have responded to Votoplam after two years in the long-term extension study. Its partner Novartis recently said the data support the ongoing Phase 3 INVEST-HD trial and will help guide next steps, including potential FDA discussions.
About the PIVOT-HD Study
PIVOT-HD began as a 12-month, placebo- controlled trial evaluating two doses of Votoplam - 5mg and 10...